Investigating cognitive fatigue in multiple sclerosis patients using brain imaging
An Examination of Cognitive Fatigue Using Functional Neuroimaging
Kessler Foundation · NCT04885894
This study is testing how new medications for relapsing-remitting multiple sclerosis affect mental tiredness during challenging tasks.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 64 Years |
| Sex | All |
| Sponsor | Kessler Foundation (other) |
| Locations | 1 site (West Orange, New Jersey) |
| Trial ID | NCT04885894 on ClinicalTrials.gov |
What this trial studies
This research examines how disease-modifying medications affect cognitive fatigue in individuals with relapsing-remitting multiple sclerosis (RRMS). The study utilizes functional neuroimaging to observe changes in brain activity related to cognitive fatigue during demanding tasks. Participants will include those newly prescribed medications like Zeposia, and the study will track cognitive fatigue over the duration of treatment. The goal is to better understand the relationship between treatment and cognitive fatigue in MS patients.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-64 with relapsing-remitting multiple sclerosis who have been newly prescribed a disease-modifying medication.
Not a fit: Patients with significant neurological events, psychiatric illnesses, or those unable to undergo MRI may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for cognitive fatigue in multiple sclerosis patients.
How similar studies have performed: Other studies have explored cognitive fatigue in MS, but this specific approach using functional neuroimaging is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 18-64. * Relapsing remitting multiple sclerosis * Been newly prescribed a new disease modifying medication for MS (either Zeposia or other high dose oral efficacy medication) * or healthy volunteer who can speak English fluently. Exclusion Criteria: * History of head injury, stroke, seizures, or any other significant neurological event other than MS * Flare up of MS symptoms within the past month. * History of significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) or a current diagnosis of Major Depressive Disorder. * Pacemaker or other implanted electrical device, brain stimulator, aneurysm clip (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and internal hearing aids \[cochlear implants\]), permanent eyeliner, implanted delivery pumps, or shrapnel fragments. * left handed. * Not able to have an MRI
Where this trial is running
West Orange, New Jersey
- Kessler Foundation — West Orange, New Jersey, United States (RECRUITING)
Study contacts
- Principal investigator: John DeLuca, PhD — Kessler Foundation
- Study coordinator: Nancy Moore
- Email: nbmoore@kesslerfoundation.org
- Phone: 973-324-8450
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Sclerosis, Relapsing-Remitting